118 related articles for article (PubMed ID: 24479691)
1. Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Rull A; Geeraert B; Aragonès G; Beltrán-Debón R; Rodríguez-Gallego E; García-Heredia A; Pedro-Botet J; Joven J; Holvoet P; Camps J
J Proteome Res; 2014 Mar; 13(3):1731-43. PubMed ID: 24479691
[TBL] [Abstract][Full Text] [Related]
2. Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: a transcriptomic and metabolomic study.
Holvoet P; Rull A; García-Heredia A; López-Sanromà S; Geeraert B; Joven J; Camps J
Food Chem Toxicol; 2015 Mar; 77():22-33. PubMed ID: 25554529
[TBL] [Abstract][Full Text] [Related]
3. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
[TBL] [Abstract][Full Text] [Related]
5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
6. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
7. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Bedoucha M; Atzpodien E; Boelsterli UA
J Hepatol; 2001 Jul; 35(1):17-23. PubMed ID: 11495036
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
[TBL] [Abstract][Full Text] [Related]
10. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes.
Zhou J; Zhou S
Eur J Pharmacol; 2010 Dec; 649(1-3):390-7. PubMed ID: 20868663
[TBL] [Abstract][Full Text] [Related]
11. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
12. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Shiri-Sverdlov R; Wouters K; van Gorp PJ; Gijbels MJ; Noel B; Buffat L; Staels B; Maeda N; van Bilsen M; Hofker MH
J Hepatol; 2006 Apr; 44(4):732-41. PubMed ID: 16466828
[TBL] [Abstract][Full Text] [Related]
13. Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice.
Jia C; Huan Y; Liu S; Hou S; Sun S; Li C; Liu Q; Jiang Q; Wang Y; Shen Z
Int J Mol Sci; 2015 May; 16(6):12213-29. PubMed ID: 26035752
[TBL] [Abstract][Full Text] [Related]
14. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
15. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.
Pan HJ; Lin Y; Chen YE; Vance DE; Leiter EH
Vascul Pharmacol; 2006 Jul; 45(1):65-71. PubMed ID: 16750656
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy.
Vikramadithyan RK; Hirata K; Yagyu H; Hu Y; Augustus A; Homma S; Goldberg IJ
J Pharmacol Exp Ther; 2005 May; 313(2):586-93. PubMed ID: 15671204
[TBL] [Abstract][Full Text] [Related]
17. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
18. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
[TBL] [Abstract][Full Text] [Related]
19. Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice.
Hemmeryckx B; Gaekens M; Gallacher DJ; Lu HR; Lijnen HR
Basic Clin Pharmacol Toxicol; 2013 Nov; 113(5):353-60. PubMed ID: 23789962
[TBL] [Abstract][Full Text] [Related]
20. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
